TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting

by NASDAQ Market News June 4, 2021

NASDAQ Market News
Click here to email author

G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Ads